Shareholders Approve 200 Million Share Increase, Authorizing 147% Potential Dilution
HUMA has more than doubled off its 52-week low of $0.547.
Summary
Humacyte shareholders approved an amendment to increase authorized common stock by 200 million shares, raising the total to 550 million and creating potential for 147.72% dilution if fully utilized.
Key Events · Financing and Capital Events · HUMA
-
Authorized Share Increase Approved
Stockholders approved an amendment to the Certificate of Incorporation, increasing the number of authorized common shares from 350,000,000 to 550,000,000. This amendment became effective on June 9, 2026.
-
Significant Potential Dilution
With 222,019,108 shares outstanding, the increase in authorized shares creates headroom for an additional 327,980,892 shares. If all authorized shares were issued, dilution would be 147.72%.
-
Annual Meeting Results
Shareholders also elected three Class II directors, approved named executive officer compensation on an advisory basis, set the frequency of future advisory votes on executive compensation to annual, and ratified Pricewaterhouse Coopers LLP as the independent auditor.
Analysis · HUMA · Life Sciences
Humacyte's stockholders approved an amendment to increase the authorized common stock from 350 million to 550 million shares. This 200 million share increase, now effective, significantly expands the company's capacity to issue new shares. With 222,019,108 shares currently outstanding, if all newly authorized shares were issued, it would result in a potential dilution of 147.72% for existing shareholders. This authorization follows previous dilutive equity raises and a 'going concern' warning, indicating the company is preparing for substantial future capital raises to support its operations.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HUMA was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $308.6M. The 52-week trading range was $0.55 to $2.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.